The goal of this clinical research study is to learn if adding ofatumumab/rituximab to the standard combination of DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, and cyclophosphamide) can help control the disease in patients with newly diagnosed or relapsed/refractory Burkitt leukemia or relapsed/refractory ALL. The safety of this drug combination will also be studied.